KRN633, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, induces intrauterine growth restriction in mice

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 98, Issue 4, 2013, Pages 297-303

  Abe, Naomichi ^a   Nakahara, Tsutomu ^a   Morita, Akane ^a   Wada, Yoshiko ^a   Mori, Asami ^a   Sakamoto, Kenji ^a   Nagamitsu, Tohru ^a   Ishii, Kunio ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Intrauterine growth restriction; Placenta; Vascular development; Vascular endothelial growth factor

Indexed keywords

KRN 633; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIRTH WEIGHT; BODY WEIGHT; CONTROLLED STUDY; DEVELOPMENTAL STAGE; FEMALE; IMMUNOHISTOCHEMISTRY; INTRAUTERINE GROWTH RETARDATION; MOUSE; NEWBORN; NONHUMAN; ORGANOGENESIS; PLACENTA; PRENATAL DEVELOPMENT; PRIORITY JOURNAL; RISK FACTOR;

MUS;

INTRAUTERINE GROWTH RESTRICTION; PLACENTA; VASCULAR DEVELOPMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ANIMALS; ANIMALS, NEWBORN; FEMALE; FETAL GROWTH RETARDATION; INTESTINE, SMALL; KIDNEY; LYMPHOID TISSUE; MALE; MICE; PANCREAS; PHENYLUREA COMPOUNDS; PLACENTA; PREGNANCY; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84885857378     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.21064     Document Type: Article

References (27)

1. Ahmad S, Ahmed A. 2004. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95:884-891.
2. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM. 2006. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 290(2):H547-H559.
3. Barker DJ. 1995. The fetal and infant origins of disease. Eur J Clin Invest 25:457-463.
4. Baschat AA, Hecher K. 2004. Fetal growth restriction due to placental disease. Semin Perinatol 28:67-80.
5. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee Kim Y, Gonçalves LF, Gomez R, Edwin S. 2004. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 190(6):1541-1547; discussion 1547-1550.
6. Cheung CY. 1997. Vascular endothelial growth factor: possible role in fetal development and placental function. J Soc Gynecol Investig 4:169-177.
7. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH. 1998. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4(3):336-340.
8. Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K. 2008. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 68(12):4754-4762.
9. Hewitt DP, Mark PJ, Waddell BJ. 2006. Glucocorticoids prevent the normal increase in placental vascular endothelial growth factor expression and placental vascularity during late pregnancy in the rat. Endocrinology 147:5568-5574.
10. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM. 2006. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290(2):H560-H576.
11. Karsdorp VH, van Vugt JM, van Geijn HP, Kostense PJ, Arduini D, Montenegro N, Todros T. 1994. Clinical significance of absent or reversed end diastolic velocity waveforms in umbilical artery. Lancet 344(8938):1664-1668.
12. Kim KE, Sung HK, Koh GY. 2007. Lymphatic development in mouse small intestine. Dev Dyn 236(7):2020-2025.
13. Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F. 2011. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res 13(3):R66.
14. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. 2003. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 88(5):2348-2351.
15. Lu F, Longo M, Tamayo E, Maner W, Al-Hendy A, Anderson GD, Hankins GD, Saade GR. 2007. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 196(4):396.e1-e7; discussion 396.e7.
16. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111(5):649-658.
17. Miquerol L, Langille BL, Nagy A. 2000. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 127:3941-3946.
18. Nakamura K, Yamamoto A, Kamishohara M, Takahashi K, Taguchi E, Miura T, Kubo K, Shibuya M, Isoe T. 2004. KRN633: a selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol Cancer Ther 3(12):1639-1649.
19. Pauli SA, Tang H, Wang J, Bohlen P, Posser R, Hartman T, Sauer MV, Kitajewski J, Zimmermann RC. 2005. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology 146(3):1301-1311.
20. Rutland CS, Mukhopadhyay M, Underwood S, Clyde N, Mayhew TM, Mitchell CA. 2005. Induction of intrauterine growth restriction by reducing placental vascular growth with the angioinhibin TNP-470. Biol Reprod 73:1164-1173.
21. Schomber T, Zumsteg A, Strittmatter K, Crnic I, Antoniadis H, Littlewood-Evans A, Wood J, Christofori G. 2009. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. Mol Cancer Ther 8:55-63.
22. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA. 2005. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 90(8):4895-4903.
23. Shibuya M. 2008. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 41:278-286.
24. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. 2003. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278(15):12605-12608.
25. Tammela T, Alitalo K. 2010. Lymphangiogenesis: molecular mechanisms and future promise. Cell 140:460-476.
26. Wada Y, Ozaki H, Abe N, Nagamitsu T, Ohta H, Nakahara T, Ishii K. 2010. Effects of KRN633, an inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, on vascular development of placenta and fetus of mid-pregnancy in mice. J Pharmacol Sci 112(3):290-298.
27. Wada Y, Ozaki H, Abe N, Mori A, Sakamoto K, Nagamitsu T, Nakahara T, Ishii K. 2013. Role of vascular endothelial growth factor in maintenance of pregnancy in mice. Endocrinology 154(2):900-910.